You are here

Optimization of a broad-spectrum Ebolavirus cell entry inhibitor chemical series as a countermeasure for parental and aerosol routes of infection

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911SR-21-C-5049
Agency Tracking Number: C2-0593
Amount: $587,720.40
Phase: Phase II
Program: SBIR
Solicitation Topic Code: CBD192-006
Solicitation Number: 19.2
Solicitation Year: 2019
Award Year: 2021
Award Start Date (Proposal Award Date): 2021-09-30
Award End Date (Contract End Date): 2023-09-30
Small Business Information
11189 Sorrrento Valley Rd, Ste 104
San Diego, CA 92121-1111
United States
DUNS: 962535782
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 KEN McCormack
 (858) 766-0495
Business Contact
 KEN McCormack
Phone: (858) 766-0495
Research Institution

Ebolavirus species including Zaire (EBOV), Sudan (SUDV) and Bundibugyo (BDBV) are responsible for severe hemorrhagic fever outbreaks with high case fatalities in Africa [1,2]. Outbreaks of EBOV in the Democratic Republic of the Congo (DRC) as well as the 2014-2016 outbreak in West Africa highlight the danger that these zoonotic viruses pose through mucosal routes of infection and secondary human to human transmission. Weaponized pathogens present an additional threat to the health protection of the warfighter and first-generation prophylactic and therapeutic medical countermeasures (MCMs) may prove inadequate in biodefense settings. Ebolaviruses present both potential public health and bioweapons threats and the development of second-generation therapeutics targeting novel mechanisms for antiviral activity may help to provide auxiliary means of protection. The objective of this proposal is to demonstrate feasibility of generating a dual use broad-spectrum small molecule ebolavirus therapeutic.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government